JP2025179094A5 - - Google Patents

Info

Publication number
JP2025179094A5
JP2025179094A5 JP2025138920A JP2025138920A JP2025179094A5 JP 2025179094 A5 JP2025179094 A5 JP 2025179094A5 JP 2025138920 A JP2025138920 A JP 2025138920A JP 2025138920 A JP2025138920 A JP 2025138920A JP 2025179094 A5 JP2025179094 A5 JP 2025179094A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
weight
morpholinophenyl
ylamino
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025138920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025179094A (ja
Filing date
Publication date
Priority claimed from JP2022562451A external-priority patent/JP7787824B2/ja
Application filed filed Critical
Publication of JP2025179094A publication Critical patent/JP2025179094A/ja
Publication of JP2025179094A5 publication Critical patent/JP2025179094A5/ja
Pending legal-status Critical Current

Links

JP2025138920A 2020-04-14 2025-08-22 アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物 Pending JP2025179094A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063009623P 2020-04-14 2020-04-14
US63/009,623 2020-04-14
US202063014277P 2020-04-23 2020-04-23
US63/014,277 2020-04-23
JP2022562451A JP7787824B2 (ja) 2020-04-14 2021-04-13 アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物
PCT/IB2021/053035 WO2021209893A1 (en) 2020-04-14 2021-04-13 Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022562451A Division JP7787824B2 (ja) 2020-04-14 2021-04-13 アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物

Publications (2)

Publication Number Publication Date
JP2025179094A JP2025179094A (ja) 2025-12-09
JP2025179094A5 true JP2025179094A5 (cg-RX-API-DMAC10.html) 2025-12-16

Family

ID=75562794

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562451A Active JP7787824B2 (ja) 2020-04-14 2021-04-13 アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物
JP2025138920A Pending JP2025179094A (ja) 2020-04-14 2025-08-22 アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022562451A Active JP7787824B2 (ja) 2020-04-14 2021-04-13 アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物

Country Status (13)

Country Link
US (2) US12138351B2 (cg-RX-API-DMAC10.html)
EP (1) EP4135669A1 (cg-RX-API-DMAC10.html)
JP (2) JP7787824B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230002656A (cg-RX-API-DMAC10.html)
CN (1) CN115484937A (cg-RX-API-DMAC10.html)
AU (2) AU2021257662B2 (cg-RX-API-DMAC10.html)
CA (1) CA3180184A1 (cg-RX-API-DMAC10.html)
IL (1) IL297240A (cg-RX-API-DMAC10.html)
MX (1) MX2022012898A (cg-RX-API-DMAC10.html)
PH (1) PH12022552454A1 (cg-RX-API-DMAC10.html)
TW (1) TWI923583B (cg-RX-API-DMAC10.html)
UY (1) UY39171A (cg-RX-API-DMAC10.html)
WO (1) WO2021209893A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
EP4349835A4 (en) * 2021-06-01 2025-06-25 Hangzhou Solipharma Co., Ltd. Hydrated crystal form of lazertinib methanesulfonate, process for its preparation and use thereof
WO2023138492A1 (zh) * 2022-01-19 2023-07-27 南京明德新药研发有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
IL326946A (en) 2023-09-05 2026-05-01 Janssen Biotech Inc Methods of treating non-small cell lung cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437006B1 (en) * 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
US6399591B1 (en) 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets
DE602007011792D1 (de) * 2006-10-27 2011-02-17 Fmc Corp Gemeinsam aufbereitete mikrokristalline cellulose und zuckeralkohol als hilfsstoff für tablettenformulierungen
EP2198857A1 (en) * 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
ES2713330T3 (es) 2009-12-11 2019-05-21 Sumitomo Dainippon Pharma Co Ltd Comprimido recubierto en seco que se desintegra oralmente
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
KR102373193B1 (ko) 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
US20160151380A1 (en) * 2013-07-12 2016-06-02 The Regents Of The University Of California Therapies for diseases caused by arthropod-borne parasites
MY179355A (en) 2013-12-12 2020-11-05 Almirall Sa Pharmaceutical compositions comprising dimethyl fumarate
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
IL261998B2 (en) * 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
UA126970C2 (uk) * 2017-01-20 2023-03-01 Екселіксіс, Інк. Комбінації кабозантинібу і атезолізумабу для лікування раку
JP2020510027A (ja) * 2017-03-08 2020-04-02 アリアド ファーマシューティカルズ,インコーポレーテッド 5−クロロ−n4−[2−(ジメチルホスホリル)フェニル]−n2−{2−メトキシ−4−[4−(4−メチルピペラジン−1−イル)ピペリジン−1−イル]フェニル}ピリミジン−2,4−ジアミンを含む医薬製剤
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
DK3658547T3 (da) 2017-07-28 2023-10-16 Yuhan Corp Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
RS63497B1 (sr) 2017-07-28 2022-09-30 Yuhan Corp Intermedijeri korisni za sintezu derivata aminopirimidina, proces za pripremu istih i proces za pripremu derivata aminopirimidina korišćenjem istih
ES2962961T3 (es) 2017-07-28 2024-03-22 Yuhan Corp Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo
CN110580014B (zh) * 2018-06-11 2021-03-30 北京京东尚科信息技术有限公司 用于控制自动导引运输车的方法、装置和系统
US12350734B2 (en) 2018-07-20 2025-07-08 Imerys Usa, Inc. Recovering sand, bentonite and organics from foundry sand waste
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CA3136632A1 (en) 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
CN113784704A (zh) 2019-04-17 2021-12-10 诺狄更斯公司 快速崩解大麻素片剂
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
MX2022001159A (es) 2019-07-31 2022-02-22 Hoffmann La Roche Nueva formulacion farmaceutica.
TW202228689A (zh) * 2020-10-09 2022-08-01 美商賽若凡斯生物製藥研發智財有限責任公司 泛jak抑制劑的調配物

Similar Documents

Publication Publication Date Title
US8673945B2 (en) Solid pharmaceutical composition comprising amlodipine and losartan
US20160129008A1 (en) Solid Dosage Form of Olmesartan Medoxomil and Amlodipine
US20190030033A1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
US20220211705A1 (en) Pharmaceutical compositions comprising afatinib
HRP20040403A2 (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same
FI3866767T3 (fi) Aminopyrimidiinijohdannaista tai sen suolaa käsittävä farmaseuttinen koostumus suun kautta annostelua varten
JP2014074067A (ja) メシル酸イマチニブのf、g、h、iおよびk結晶形
JP2020073513A (ja) α,ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
TWI574690B (zh) 立即釋放4-甲基-3[[4-(3-吡啶基)-2-嘧啶基]胺基]-n-[5-(4-甲基-1h-咪唑-1-基)-3-(三氟甲基)苯基]苯甲醯胺調配物
US6001845A (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
UA69441C2 (uk) Саредутант як агент для лікування або попередження основних депресивних розладів
FI3993777T3 (fi) Kompressoidut masitentaanikoostumukset, menetelmät ja niiden käytöt
US6136818A (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
JP2022097443A (ja) ビラスチンを含有する口腔内崩壊錠
CN102836161A (zh) 一种以奥美沙坦酯与苯磺酸氨氯地平及氢氯噻嗪混合组成的药物的复方制剂
JPH05194228A (ja) ダピプラゾール含有経口投与用固体医薬組成物
WO2013100870A1 (en) New antipsychotic compositions
JP2010516712A5 (cg-RX-API-DMAC10.html)
JP7437039B2 (ja) 錠剤
JP2024090218A (ja) 崩壊遅延を改善したゾニサミド含有口腔内速崩壊錠
GB2471970A (en) Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide
KR20160014618A (ko) 유기산과의 아고멜라틴 공-결정체 형태로 아고멜라틴을 포함하는 약제학적 제형
TH2101002156A (th) องค์ประกอบทางเภสัชกรรมสำหรับการให้ทางปากซึ่งประกอบรวมด้วยอนุพันธ์อะมิโนไพริมิดีนหรือเกลือของสารนั้น
JP2007525502A (ja) コナゾール類の新規な結晶形態並びにそれらの製造および使用方法
JPWO2019124487A1 (ja) オミデネパグの組合せ